Studies have shown that the anticholesterol drug rosuvastatin is associated with an increased risk of hematuria, proteinuria, and replacement therapy-induced renal failure (KFRT) compared to the use of atorvastatin. Journal of the American Society of Nephrology published in the latest issue.
A research team led by Jung-Im Shin from the Johns Hopkins Bloomberg School of Public Health analyzed 152,101 new users of rosuvastatin and 790,799 new users of atorvastatin between 2011 and 2019 using confirmed electronic health record data.
We estimated the inverse probability of rosuvastatin-associated hematuria, proteinuria, and treatment-weighted risk ratios for KFRT.
The dose effect of rosuvastatin was investigated for hematuria and proteinuria.
During a median follow-up of 3.1 years, the team identified hematuria in 2.9% of patients and proteinuria in 1.0%.
Rosuvastatin use was associated with an increased risk of hematuria, proteinuria, and KFRT compared to atorvastatin (hazard ratios: 1.08, 1.17, and 1.15, respectively).
44% of patients with an estimated glomerular filtration rate <30 mL/min/1.73 m2 were treated with high-dose rosuvastatin (up to a daily dose of 10 mg) despite current labels suggesting a dose reduction for patients with severe chronic kidney disease (10 mg/day). 20 mg or 40 mg).
The higher the rosuvastatin dose, the higher the risk for hematuria and proteinuria.
“This finding suggests the need to be more cautious in prescribing and monitoring rosuvastatin, especially in high-dose patients or patients with severe chronic kidney disease,” the researchers wrote.
Meanwhile, Novartis’ Crestor for rosuvastatin and Pfizer’s Lipitor for atorvastatin and many generics are marketed.
Send articles on social media